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Abstract
Objectives: To test the efficacy of 10% chlorhexidine (CHX) dental varnish applied
to the mothers’ dentition in preventing caries in American Indian children.
Methods: This was a placebo-controlled, double-blind, randomized clinical trial.
Mother–child pairs were enrolled when the child was 4.5-6.0 months. Mothers
received 4 weekly applications of the study treatment (CHX or placebo) followed by
single applications when her child was age 12 and 18 months. Children received
caries examinations at enrollment, 12, 18 and 24 months. Analyses were limited to
the intent-to-treat (ITT) group: children whose mothers received the first study
treatment and who received at least one post-baseline exam. The outcome variable
was the number of new carious surfaces (NNCS) at the child’s last visit. Wilcoxon
nonparametric and Fisher’s exact tests were used to test differences between the
active and placebo groups.
Results:We randomized 414 mother–child pairs, with 367 (88.6%) included in the
ITT group (active = 188, placebo = 179). The proportion of children caries-free at
their final exam was 51.1% and 50.8% for the active and placebo groups (P > 0.99).
The mean NNCS for the active and placebo groups was 3.82 (standard deviation
[SD] = 8.18) and 3.80 (SD = 6.08), respectively (P = 0.54). The proportion with
NNCS > 6 was 18.1% for active children versus 27.9% for placebo (relative risk
[RR] = 0.65,P = 0.03).The number needed to treat to shift one child fromNNCS> 6
to a lower severity was 10.2.
Conclusions: In this population CHX varnish did not reduce the mean NNCS or
proportion of children with caries, but did reduce the proportion with severe caries.
Introduction
Caries in the primary dentition (commonly referred to as
early childhood caries, or ECC) is the most common pediat-
ric chronic disease, with a prevalence of 28% in US children
2-5 years of age (1). Low-income and minority children are
disproportionately affected by caries, with American Indian
and Alaskan Native (AI/AN) children being one of the racial/
ethnic groups at highest risk (2). Despite decades of ECC
control efforts by AI/AN communities and Indian Health
Service (IHS) – the federal agencywhosemission is to provide
health services to AI/AN – little progress has been made. The
IHS ECC-prevention efforts have focused primarily on com-
munity water fluoridation, behavior modification for the
mother regarding the child’s diet and oral hygiene, and appli-
cation of fluoride varnish (FV) in both clinical and commu-
nity settings. However, the outcome of these efforts was
recently described as “minor, transient victories, at best” (3).
Caries is a multifactorial disease, with the presence of cari-
ogenic bacteria being a necessary but not sufficient compo-
nent. The majority of the literature suggests that children
acquire cariogenic bacteria by vertical transmission from the
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mother (4,5), although horizontal transmission has also been
identified (6). Once teeth are colonized, cariogenic bacteria
produce acid when exposed to sugar, resulting in demineral-
ization of the enamel if the acid is of sufficient quantity and
duration (7). The newly emerged primary dentition is espe-
cially susceptible to caries because the hydroxyapatite of the
enamel is highly susceptible to acid dissolution (8), and
requires time to “mature.” There are no published reports on
the level of cariogenic bacteria among AI/AN children,
although there is documentation that AI/AN have a much
higher incidence and prevalence of other infectious diseases
of childhood (9,10).
Although never studied in AI/AN populations, there are a
number of reports of attempting to reduce the rate of ECC by
interfering with the vertical transmission of cariogenic bacte-
ria from mother to infant. Kohler (11) treated caries-active
mothers with either what was considered the standard of care
orwith the combination of dental restorations, chlorhexidine
(CHX)mouth rinse, FV,dietary counseling, and oral hygiene.
Children of treated mothers exhibited delayed colonization
by mutans streptococci (MS) and a significant reduction in
caries that was still evident when the children were 7 years
(12).
There is extensive literature on the use of CHX-containing
products in different vehicles and concentrations to prevent
caries, with results as varied as the methods. Recent reviews
(13-15) found evidence that in selected populations at certain
concentrations and frequencies, CHX may be an effective
agent in reducing caries, but that overall, the data are incon-
clusive. Some of these studies included using CHX on the
mother’s dentition in an attempt to interrupt or delay trans-
mission of cariogenic bacteria to the child, againwith varying
results. The purpose of this research was to test the efficacy
of CHX varnish in reducing the prevalence and severity of
ECC among high-risk AI/AN children through interrupting
the transmission of cariogenic bacteria from mother to
child by periodic treatment of the mother with a 10% CHX
formulation found effective in reducing decay in adults with
xerostomia (16).
Materials and methods
Design
This was a placebo-controlled (1:1), double-blind, parallel
group randomized clinical trial of the efficacy of a 10% CHX
varnish applied to the mothers’ dentition in preventing ECC.
Mother–child pairswere enrolledwhen the childwas between
4.5 and 6.0 months of age. After enrollment, each mother
received four weekly applications of the study treatment
(CHX or a placebo) followed by single applications when her
childwas approximately 12 and 18months of age for a total of
six treatments (Table 1). At enrollment and again at the 12-
and 18-month exams, themothers completed questionnaires
on their interim medical history, concurrent medications,
and adverse effects from the study medication. The children
received comprehensive surface-specific caries examinations
at enrollment and when the child was approximately 12, 18,
and 24months old.Children received a FV treatment after the
Table 1 Treatment (for Mothers) and Exam (for Children) Timeline and Number Completed*
Interval between treatments
Intent to treat
n = 367
Active Placebo
n/a Treatment 1 and caries exam Treatment 1 and caries exam
n = 188 mother–child dyads n = 179 mother–child dyads
1 week (5-14 days) Treatment 2 Treatment 2
n = 182 mothers n = 173 mothers
1 week (5-14 days) Treatment 3 Treatment 3
n = 177 mothers n = 170 mothers
1 week (5-14 days) Treatment 4 Treatment 4
n = 174 mothers n = 169 mothers
6 months ( 14 days) Treatment 5 and caries exam Treatment 5 and caries exam
n = 157 mothers n = 152 mothers
n = 177 children n = 165 children
6 months ( 14 days) Treatment 6 and caries exam Treatment 6 and caries exam
n = 139 mothers n = 129 mothers
n = 165 children n = 152 children
6 months ( 14 days) (end of
study)
Caries exam Caries exam
n = 164 children n = 156 children
* Per protocol visit interval; individuals who completed the visit outside of the protocol interval are
also included in the counts.
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12- and 18-month exams – the standard of care at the study
sites. The FDA approved this Phase III clinical trial under
IND #45,466.
Study sites
Participants were recruited from four different AI communi-
ties in Oregon, Washington, and Arizona – all with fluori-
dated water systems. The study was conducted at the local
IHS or tribally operated community dental clinic. At three of
the sites, the facility dentists were trained as examiners, while
the fourth and largest site hired a dentist examiner specifically
for the study.
Participants
Women were eligible to participate if they could provide
informed consent, had at least 20 natural teeth, had unre-
stored caries or a previous child with documented ECC, and
had a child between 4.5 and 6.0 months of age with or
without teeth. Exclusion criteria included the presence of
orthodontic appliances and pregnancy. Prior to enrollment,
the mother’s cavitated carious lesions were restored. The
Institutional Review Board of record and the local tribal
health authority for each community approved the proto-
col, and written informed consent was obtained from all
participants.
Randomization and study treatments
Study sites received consecutively numbered boxes of the
study productwhichwere numbered by the research pharma-
cist prior to shipment. Each box contained separate vials for
each study visit. As participants were enrolled, they were
assigned the next numbered product box. Because the active
and placebo study products were identical in color, smell,
taste, and viscosity, neither the participants nor study staff
knew whether the product was active or placebo. Study treat-
ments were applied in a dental clinic setting by trained
hygienists or dental assistants after a brief rubber cupprophy-
laxis. The study treatments were applied in two stages: Stage 1
contained either 10%CHXdiacetatew/v suspended in a solu-
tion of Sumatra benzoin and alcohol (the active treatment) or
only the Sumatra benzoin and alcohol solution (the placebo
treatment); Stage 2 was a proprietary aqueous dispersion of
inertmethacrylate approved for use by the FDAunder license
K023671. The stage 2 coating is designed to prolong the
contact time between the CHX and the tooth. For partici-
pants in the active treatment arm, the mean dose of CHX at
each application visit was 37.4 mg (14); the cumulative
mean dose was 224 mg. The visits for the mother–child pair
took 45-60 minutes each for the four visits in which the
mothers filled out the interim history questionnaires in addi-
tion to getting a caries examination and study medication
application, and about 15 minutes each for the four other
visits.
Child caries examination and
primary outcome
Caries were diagnosed visually by calibrated examiners in a
dental clinic setting using amirror, periodontal probe, dental
light, and air. We used the diagnostic nomenclature of Pitts
and Fyffe (17): non-cavitated lesions (d1); lesions where the
cavitation extends into,but not through, the enamel (d2); and
cavitated lesions that involve the dentine (d3).At the onset of
the study, an examiner calibration session was held with a
gold standard examiner,1 followed by recalibrations at
approximately 6-12-month intervals. Because of staff turn-
over at the sites that used facility dentists as examiners, there
were a total of 17 examiners among the four sites. Each new
examiner received the same calibration training from the
same trainer before examining study participants. The inter-
examiner reliability kappa scores for examiners compared to
the standard ranged from 0.54 to 0.77, and intra-examiner
kappaswere 0.77-1.00.The primary outcome variablewas the
child’s number of new carious surfaces (NNCS) at the last
post-baseline visit.
Definition of the intent-to-treat
population evaluated
For sample size calculation, we estimated a mean baseline
NNCS of 4.0 (standard deviation [SD] 3.0), with a minimal
clinical improvement of 20%, resulting in a target completion
of 221 children in each treatment group (total 442). The
intent-to-treat (ITT) population consisted of children of ran-
domized mothers who received the first study medication
application and who returned with their child for at least one
of the three post-baseline exams. For children who did not
complete all visits according to study protocol, the NNCS
score from the last post-baseline examination was carried
forward (last observation carried forward).
Statistical analysis
The children’s NNCS scores at their last post-baseline visit
were analyzed as a continuousmeasure for themeanNNCS –
the primary outcome variable. They were also analyzed as a
categorical variable based on two post-randomization sets of
cutoffs. Categorization #1 (NNCS = 0, NNCS = 1-5, NNCS
6) was defined as a proxy for clinical severity based on the
expert opinion of the facility dentists participating in our
1 David Banting, DDS, DDPH, MSc, University of Western
Ontario.
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study that in their specific communities any child at 24
months of age having 6 cavitated tooth surfaces would
likely require in-hospital treatment under general anesth-
esia (GA). Categorization #2 (NNCS = 1-3, NNCS = 4-7,
NNCS 8) is the tertile distribution of the NNCS scores for
placebo children who had >0 NNCS scores at their last exam.
These categorizations were used to determine whether, irre-
spective of the mean NNCS, there was any shift in the distri-
bution of caries severity as a result of the treatment
intervention.Todetermine the effect of FV applications to the
children, we analyzed the frequency distribution of the
number of FV applications and used this for an adjusted
analysis. The Wilcoxon nonparametric test was used to test
the differences between the active treatment and placebo
groups for continuousmeasures. The nonparametric test was
used because it is more robust to departures from normality
and outliers, and in the dataset being evaluated, there were
several large outliers. The Fisher’s exact test was used to test
for differences in the proportion of study participants in the
two different categorization schemes between the active and
placebo groups.All analyses were conducted using SAS/STAT
softwareVersion 9.2 (18).
Results
Study population
We randomized a total of 414 AI/AN mother–child pairs, of
whom 367 (the ITT group) returned for at least one post-
baseline visit (Figure 1). At enrollment, these 367 mothers
ranged in age from14.1 to 43.5 years (mean = 26.8, SD = 6.4).
At enrollment, children were 4.5-6months old (mean = 5.26,
SD = 0.64), and at the endof studywere 22.0-30.3months old
(mean = 24.3, SD = 1.4). A total of 188 mother–child pairs
were in the active treatment group, while 179 were in the
placebo group. There was no difference between the active
and placebo group in the children’s mean age at enrollment
or age at their last exam (Table 3). There were no serious
study-related adverse events to either mothers or children.
Protocol compliance
There was no difference (P = 0.9) between active versus
placebo in protocol compliance: 104 mother–child pairs
(active n = 54, placebo n = 50) completed all activities per
protocol; 119 (active n = 61, placebo n = 58) completed six of
the study medication applications but not per protocol time-
line; 99 (active n = 49, placebo n = 50) had at least five of the
six applications; and 45 (active n = 24, placebo n = 21) had
less than five applications (Table 2).
Caries increment
The mean NNCS did not differ between the active and
placebo groups: 3.82 (SD = 8.18) versus 3.80 (SD = 6.08),
respectively (P = 0.54) (Table 3). The intraquartile range was
0-4 for the active group and 0-6 in the placebo group, indicat-
ing that 75%of the individuals in the active group hadNNCS
 4 compared to 75% who had NNCS  6 in the placebo
group. The proportion of children caries-free at their final
examwas the same for active (51.1%) versus placebo (50.8%)
(P > 0.99; Table 4).
An analysis of the children’s end of study NNCS scores
using the post-randomization clinical severity Categoriza-
tion #1 (NNCS = 0, 1-5 or  6) resulted in a difference
(P = 0.03) in the distribution of caries scores between the
active and placebo groups, with fewer active children in the
most severe category (NNCS 6) (Table 4). The relative risk
for havingNNCS 6was reduced by 35.2%among the active
group. Severity Categorization #2 compared only the 187
children with NNCS > 0 at their final examination using the
tertile distribution of caries from the placebo group
(NNCS = 1-3, 4-7, and 8). Using this distribution resulted
in a nonsignificant (P = 0.11) trend for a greater proportion
of the active children to be in less severe tertiles (Table 5).
We used the frequency distribution of FV applications for
adjusted analysis. Because of an error in printing the paper
Case Record Forms for the study, FV status was not reliably
recorded at two of the four study sites, so we evaluated the
effects on the children (n = 295) at the twoother sites. Fisher’s
exact test resulted in a nonsignificant trend (P = 0.16) for a
greater proportion of active (74.2%) than placebo (66.2%)
children to have received 2 versus 0-1 FV applications.
However, the mean NNCS was the same (4.2) for placebo
children who received 2 (n = 98) versus 0-1 (n = 50) FV.
Adjusted analysis controlling for the frequency of FV applica-
tion did not change the result of the distribution for severity
Categorization #1 or #2 as the parameter estimates of treat-
ment effect adjusted and unadjusted were essentially the
same.
Number needed to treat
The number needed to treat (NNT) metric is a useful way to
assess the practicality of implementing a specific preventive
intervention (19). Using severity Categorization #1, the NNT
was 10.2 [1/(27.9%–18.1%)] to shift one child from themost
severe caries category (NNCS 6) to a less severe outcome.
Discussion
This study is the first completed randomized controlled clini-
cal trial intended to prevent ECC among AI/AN children by
interrupting the vertical transmission of cariogenic bacteria –
primarily MS, but not excluding others – from mother to
child by treating only the mother. This study was initiated in
the context of a very high prevalence, severity, and morbidity
from ECC inmany AI/AN communities.
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There were acknowledged limitations of the study – fore-
most being the absence of a microbiological assessment for
either mothers or children. Because transmission of cari-
ogenic bacteria was the issue of concern, DNA fingerprinting
would have been required, which would have greatly
exceeded the budgetary and logistic capability of the study.
There were ongoing recruitment and retention problems at
two sites; thus we did not achieve our goal of 442 completed
children for analysis. Given that the study was conducted
using the community dental facility dentists as examiners,
we used multiple examiners at each site, although all
were trained by the same individual. We did not control for
Figure 1 Number of study participants, by treatment group and protocol compliance.
Table 2 Protocol Compliance for Intent-to-Treat Population, by
Treatment
Protocol compliance
Active Placebo Total
n = 188 n = 179 n = 367
6 treatments per protocol 54 50 104
6 treatments but not per protocol 61 58 119
5 of 6 treatments 49 50 99
4 of 6 treatments 14 14 28
3 of 6 treatments 6 3 9
2 of 6 treatments 4 4 8
1 of 6 treatments 0 0 0
Overall P-value = 0.9 (Fisher’s exact test).
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potential confounding variables such as antibiotic treatment
for infectious disease, although the randomized placebo
design should minimize any effect from these. Last, a cost–
benefit analysis was beyond the scope of the study.
We found no difference between active versus placebo in
either the mean NNCS for the children or proportion of
caries-free children. Despite this, in each of two analyses
based on post-randomization categorization by clinical
severity, there was a trend among active children toward
reduced caries severity (Table 4 and 5). This suggests that for
children at the highest risk, mean NNCS and the proportion
of caries-free children may not adequately describe changes
in disease severity. The need for a newmetric for caries in the
primary dentition that correlates well with morbidity was
emphasized in the 2010 Symposium on ECC among AI/AN
children sponsored by the American Dental Association
(http://www.ada.org/5154.aspx).
For very high-risk populations, themost important issue is
whether morbidity from severe ECC, such as pain, infection,
and hospitalization, can be prevented through an interven-
tion. A good model for this construct found in the pediatric
infectious disease literaturemay be the varicella (chickenpox)
vaccine. A review found that the vaccine was 84.5% effective
(range 44%–100%) in preventing all cases of varicella, but
100% effective in preventing severe varicella (20). This does
not imply that varicella and caries are equivalent in all
attributes, but rather provides a documented example that
interventions may achieve reductions in the proportion of
individuals with severe diseasewhile not eliminating all cases.
Similarly,ourprimary goal forECCpreventionamongAI/AN
children is to reduce the prevalence of severe cases, especially
thoserequiringrestorativecareunderGA(21,22).Thecostof a
full mouth GA restoration in a child has been estimated at
$2,000-10,000 per case. Thus, both the human and financial
costs are extremely high (23). Anecdotally, in many AI/AN
communities,>25%of all children require restorations under
GAfor severeECCprior toentry into thefirstgrade.This com-
pares to published data from two administrative databases
showing a rate of about 0.2%of non-AI/ANchildren (24).
Wehave nodata on the subsequent caries experience of our
study children to determine how many GA cases were pre-
vented by the intervention used, and there is no national stan-
dard for assessing disease burden from ECC. Therefore,
we evaluated the study results by two proxies for disease
morbidity (severity categorizations 1 and 2). The expert
Table 3 Number of New Carious Surfaces (NNCS) and Age at the Final
Exam – Intent-to-Treat Population
Variable
Treatment group
P-value*
Active Placebo
n = 188 n = 179
NNCS
Mean (SD) 3.82 (8.18) 3.80 (6.08) 0.540
Median (IQR) 0 (0-4) 0 (0-6)
Range 0-67 0-27
Child’s age (months)
Mean (SD) 23.0 (3.6) 23.2 (3.7) 0.699
Range 10.9-30.5 10.8-30.1
* Wilcoxon nonparametric test.
Table 4 Distribution of Caries by Categorization #1 (NNCS = 0, 1-5, 6) at Final Exam – Intent-to-
Treat Population
Variable Statistic
Treatment group
RR
Overall
P-value*Active Placebo
Severity (categorization #1) N 188 179 0.029
NNCS = 0 96 (51.1%) 91 (50.8%) 1.01
NNCS = 1-5 58 (30.9%) 38 (21.2%) 1.45
NNCS6 34 (18.1%) 50 (27.9%) 0.65
* Fisher’s exact test.
Table 5 Distribution of Caries by Categorization #2 (NNCS = 1-3, 4-7,  8) Among Caries-Active
Children at the Final Exam – Intent-to-Treat Population
Variable Statistic
Treatment group
RR
Overall
P-value*Active Placebo
Severity (categorization #2) N 92 88
NNCS = 1-3 42 (45.7%) 27 (30.7%) 1.49 0.113
NNCS = 4-7 24 (26.1%) 31 (35.2%) 0.74
NNCS  8 26 (28.3%) 30 (34.1%) 0.83
* Fisher’s exact test.
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opinion of the facility dentists participating in our study was
that a caries dmfs (decayed, missing or filled surfaces) score
6 for 24 months old children would likely require
in-hospital GA treatment. Based on this, we initially com-
pared the active versus placebo groups for the distribution of
caries when categorized into three groups: NNCS = 0, 1-5,
6. This resulted in a statistically significant change in the
distribution of active versus placebo children,with 32% fewer
children in the active group being in the 6 category com-
pared to the placebo group (P = 0.03).
Given the absence of data showing the proportion of chil-
dren who with any given dmfs score ultimately require treat-
ment under GA, this categorization of children into these
groups was admittedly a somewhat arbitrary attempt to cor-
relate dmfswithmorbidity.Thus, for further analysis,we next
evaluated only the caries-active children by a “natural” distri-
bution of tertiles (NNCS = 1-3, 4-7, 8) derived from the
NNCS in our placebo group. This analysis resulted in a favor-
able but nonsignificant (P = 0.11) trend for a higher propor-
tion of placebo children to be in the more severe two tertiles
compared to the active children.
A remarkable incidental finding of our study was that by
age 24months,49.2%of placebo childrenhad cavitated caries
(mean NNCS = 3.8) despite the study protocol specifying
that children receive FV at 12 and 18 months. This contrasts
with the report by Weintraub (25) that found caries preven-
tion efficacy of even one FVannually.However, althoughpur-
ported to be a study of high-risk children (“low income,
underserved populations”), this study featured the method-
ological curiosity of excluding from enrollment all the
highest-risk children – namely those who had extant caries at
the screening exam (26). Our finding of very limited preven-
tive effectiveness of FV in our study population is consistent
with the report by Holve (27) in which the“successful” group
of AI/AN children who had4 applications of FV at ages 9,
12, 15, 18, and 24 months nonetheless had a mean dmfs of
15.6 at age approximately 52 months.
There are a number of plausible reasons for the failure to
achieve a positive treatment effect on the mean NNCS. The
schedule of CHX varnish for the mothers may not have been
adequate to inhibit transmission of all their cariogenic bacte-
ria. Also, some of the children may have acquired their cari-
ogenic bacteria from someone other than the mother; a
recent report by Mitchell (28) found that 74% of children
scheduled for full mouth restoration under GA had Strepto-
coccus mutans subtypes that did not match their mothers’
S. mutans. There are no published reports of the proportion
of AI/AN children who acquire S. mutans from sources other
than the mother, nor of correlation of caries severity with the
source of transmission. Given the early and severe ECC that
many AI/AN children develop, the microbiological para-
digms that apply in lower-risk communities may not be
applicable to AI/ANmothers and children.
Future research needed
Considering that almost 50% of the children in our placebo
group had cavitated caries at age 24 months, clearly addi-
tional research is need to further quantify, understand, and
control ECC in AI/AN children. Future research in this area
should address transmission of cariogenic bacteria in con-
junction with measures of reduction of incidence and mor-
bidity from caries.
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